Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 3
2014 1
2015 3
2016 1
2017 1
2020 3
2021 2
2023 2
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "EGFR-related lung cancer"
Page 1
JMJD5 inhibits lung cancer progression by facilitating EGFR proteasomal degradation.
Shen J, Liu G, Qi H, Xiang X, Shao J. Shen J, et al. Cell Death Dis. 2023 Oct 9;14(10):657. doi: 10.1038/s41419-023-06194-0. Cell Death Dis. 2023. PMID: 37813845 Free PMC article.
Aberrant activation of epidermal growth factor receptor (EGFR) signaling is closely related to the development of non-small cell lung cancer (NSCLC). However, targeted EGFR therapeutics such as tyrosine kinase inhibitors (TKIs) face the challenge of EGFR mutation-me …
Aberrant activation of epidermal growth factor receptor (EGFR) signaling is closely related to the development of non-small cell lung …
Celecoxib and Afatinib synergistic enhance radiotherapy sensitivity on human non-small cell lung cancer A549 cells.
Zhang P, Song E, Jiang M, Song Y. Zhang P, et al. Int J Radiat Biol. 2021;97(2):170-178. doi: 10.1080/09553002.2021.1846817. Epub 2020 Nov 12. Int J Radiat Biol. 2021. PMID: 33164600
PURPOSE: Radioresistance is highly correlated with radiotherapy failure in clinical cancer treatment. In the current study, we sought to examine the efficacy of Celecoxib and Afatinib co-treatment as radiosensitizers in the management of non-small cell lung cance …
PURPOSE: Radioresistance is highly correlated with radiotherapy failure in clinical cancer treatment. In the current study, we sought …
Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC.
Zheng MM, Li YS, Tu HY, Jiang BY, Yang JJ, Zhou Q, Xu CR, Yang XR, Wu YL. Zheng MM, et al. J Thorac Oncol. 2021 Feb;16(2):250-258. doi: 10.1016/j.jtho.2020.10.008. Epub 2020 Oct 26. J Thorac Oncol. 2021. PMID: 33122107 Free article.
Patients with T790M-negative CSF, EGFR exon 21 L858R mutation, concurrent FGF3 alteration, and over first-line osimertinib had shortened iPFS. In cohort 2, possible EGFR-related and EGFR-independent resistance mechanisms were found including C797S mutation, MET dysr …
Patients with T790M-negative CSF, EGFR exon 21 L858R mutation, concurrent FGF3 alteration, and over first-line osimertinib had shortened iPF …
Sulforaphane attenuates EGFR signaling in NSCLC cells.
Chen CY, Yu ZY, Chuang YS, Huang RM, Wang TC. Chen CY, et al. J Biomed Sci. 2015 Jun 3;22(1):38. doi: 10.1186/s12929-015-0139-x. J Biomed Sci. 2015. PMID: 26036303 Free PMC article.
BACKGROUND: EGFR, a receptor tyrosine kinase (RTK), is frequently overexpressed and mutated in non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) have been widely used in the treatment of many cancers, including NSCLC. ...The sensitivity of NSCLC …
BACKGROUND: EGFR, a receptor tyrosine kinase (RTK), is frequently overexpressed and mutated in non-small cell lung cancer (NSC …
The emerging role of noncoding RNAs in the EGFR signaling pathway in lung cancer.
Mohan S, Hakami MA, Dailah HG, Khalid A, Najmi A, Zoghebi K, Halawi MA. Mohan S, et al. Pathol Res Pract. 2024 Jan;253:155016. doi: 10.1016/j.prp.2023.155016. Epub 2023 Dec 5. Pathol Res Pract. 2024. PMID: 38070221 Review.
The clinical implications of ncRNAs in EGFR-driven lung cancer are substantial. These molecules exhibit diagnostic potential as robust biomarkers for early cancer detection and personalized treatment. ...This review explores the increasing evidence supporting …
The clinical implications of ncRNAs in EGFR-driven lung cancer are substantial. These molecules exhibit diagnostic potential a …
Insensitivity of oncogenic EGFR R776L mutation to EGFR inhibitors in lung cancer.
Wang Y, Hu C, Yu H, Hu J, Zhou Z, Fu N, Huang X, Kong F, Wang W, Liu J. Wang Y, et al. Lung Cancer. 2024 Mar;189:107495. doi: 10.1016/j.lungcan.2024.107495. Epub 2024 Jan 28. Lung Cancer. 2024. PMID: 38335691
Non-small cell lung cancers (NSCLC) account for 85 % of total lung cancers. Mutation in EGFRdrives the progress of NSCLSs with high mortality rate. ...We also explored the oncogenic feature of single R776L mutation by Ba/F3 isogenic cells and found that, EGFR R776L …
Non-small cell lung cancers (NSCLC) account for 85 % of total lung cancers. Mutation in EGFRdrives the progress of NSCLSs with …
Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating HSP90-EGFR association.
Yang YC, Cheng TY, Huang SM, Su CY, Yang PW, Lee JM, Chen CK, Hsiao M, Hua KT, Kuo ML. Yang YC, et al. Oncogene. 2016 Jun 30;35(26):3387-98. doi: 10.1038/onc.2015.397. Epub 2015 Oct 26. Oncogene. 2016. PMID: 26500058
Secondary mutation of epidermal growth factor receptor (EGFR) resulting in drug resistance is one of the most critical issues in lung cancer therapy. Several drugs are being developed to overcome EGFR tyrosine kinase inhibitor (TKI) resistance. Here, we report that …
Secondary mutation of epidermal growth factor receptor (EGFR) resulting in drug resistance is one of the most critical issues in lung …
Detection of EGFR mutations in patients with non-small cell lung cancer by high resolution melting. Comparison with other methods.
Martínez-Carretero C, Pascual FI, Rus A, Bernardo I. Martínez-Carretero C, et al. Clin Chem Lab Med. 2017 Oct 26;55(12):1970-1978. doi: 10.1515/cclm-2016-0353. Clin Chem Lab Med. 2017. PMID: 28432840
BACKGROUND: The discovery of mutations in the epidermal growth factor receptor gene (EGFR) related to the clinical response to tyrosine kinase inhibitors, has transformed the management of non-small cell lung cancer (NSCLC). ...
BACKGROUND: The discovery of mutations in the epidermal growth factor receptor gene (EGFR) related to the clinical response to …
Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice.
Chung CT, Yeh KC, Lee CH, Chen YY, Ho PJ, Chang KY, Chen CH, Lai YK, Chen CT. Chung CT, et al. Pharmacol Res. 2020 Nov;161:105183. doi: 10.1016/j.phrs.2020.105183. Epub 2020 Sep 5. Pharmacol Res. 2020. PMID: 32896579 Free article.
Non-small-cell lung cancer (NSCLC) is a leading cause of cancer-related death worldwide. NSCLC patients with overexpressed or mutated epidermal growth factor receptor (EGFR) related to disease progression are treated with EGFR-tyrosine kinase in …
Non-small-cell lung cancer (NSCLC) is a leading cause of cancer-related death worldwide. NSCLC patients with overexpres …
Twenty-One Novel EGFR Kinase Domain variants in Patients with Nonsmall Cell Lung Cancer.
Hasenahuer MA, Parisi G, Gautier M, Lazarowski A, Bramuglia GF, Fornasari MS. Hasenahuer MA, et al. Ann Hum Genet. 2015 Nov;79(6):385-93. doi: 10.1111/ahg.12127. Epub 2015 Sep 29. Ann Hum Genet. 2015. PMID: 26420346
Somatic sequence variants in the epidermal growth factor receptor (EGFR) kinase domain are associated with sensitivity to tyrosine kinase inhibitors (TKIs) in patients with nonsmall cell lung cancer (NSCLC). Patients exhibiting sequence variants in this domain that …
Somatic sequence variants in the epidermal growth factor receptor (EGFR) kinase domain are associated with sensitivity to tyrosine kinase in …
15 results